Effect of bisphosphonate and denosumab treatment on TBS in Japanese breast cancer patients with AIBL.

IF 2.4 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of Bone and Mineral Metabolism Pub Date : 2024-11-01 Epub Date: 2024-08-13 DOI:10.1007/s00774-024-01542-2

Emi Onuma, Shin Saito, Taku Tsuburai, Hiromi Yoshikata, Shoko Adachi, Shinya Yamamoto, Kazutaka Narui, Tomonari Hayama, Mariko Murase, Taichi Mizushima, Etsuko Miyagi, Hideya Sakakibara, Ryoko Asano

{"title":"Effect of bisphosphonate and denosumab treatment on TBS in Japanese breast cancer patients with AIBL.","authors":"Emi Onuma, Shin Saito, Taku Tsuburai, Hiromi Yoshikata, Shoko Adachi, Shinya Yamamoto, Kazutaka Narui, Tomonari Hayama, Mariko Murase, Taichi Mizushima, Etsuko Miyagi, Hideya Sakakibara, Ryoko Asano","doi":"10.1007/s00774-024-01542-2","DOIUrl":null,"url":null,"abstract":"Introduction: Bisphosphonates and denosumab increase bone mineral density (BMD) for osteoporosis treatment in patients with aromatase inhibitor-associated bone loss (AIBL). This study aimed to directly compare bisphosphonates with denosumab in treating patients with AIBL and to determine the effect of denosumab on the trabecular bone score (TBS).Materials and methods: Thirty-nine patients with AIBL receiving osteoporosis treatment (21 in the bisphosphonates group and 18 in the denosumab group) were retrospectively evaluated for changes in lumbar spine and femoral BMD, lumbar spine bone quality (assessed by TBS), and blood bone metabolic markers. The Mann-Whitney and Wilcoxon tests were used for statistical evaluation.Results: After 24 months of treatment, the lumbar spine BMD change rate was 5.82 ± 1.10% with bisphosphonates and 10.49 ± 1.20% with denosumab, with the change rate of denosumab significantly increasing over that of bisphosphonates. The change rate in femoral BMD was 2.69 ± 1.16% with bisphosphonates and 2.95 ± 1.26% with denosumab, with no significant difference between the two groups. The rate of decrease in tartrate-resistant acid phosphatase isoform 5b was significantly higher in the denosumab group. The change rate in TBS at 24 months of treatment was 0.53 ± 1.26% in the bisphosphonates group and 1.08 ± 1.33% in the denosumab group, with no significant difference between the two groups. After 24 months, TBS remained stable.Conclusion: Both bisphosphonates and denosumab may increase BMD, improve bone metabolism, and inhibit bone quality loss in patients with AIBL.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"699-709"},"PeriodicalIF":2.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone and Mineral Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00774-024-01542-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Bisphosphonates and denosumab increase bone mineral density (BMD) for osteoporosis treatment in patients with aromatase inhibitor-associated bone loss (AIBL). This study aimed to directly compare bisphosphonates with denosumab in treating patients with AIBL and to determine the effect of denosumab on the trabecular bone score (TBS).

Materials and methods: Thirty-nine patients with AIBL receiving osteoporosis treatment (21 in the bisphosphonates group and 18 in the denosumab group) were retrospectively evaluated for changes in lumbar spine and femoral BMD, lumbar spine bone quality (assessed by TBS), and blood bone metabolic markers. The Mann-Whitney and Wilcoxon tests were used for statistical evaluation.

Results: After 24 months of treatment, the lumbar spine BMD change rate was 5.82 ± 1.10% with bisphosphonates and 10.49 ± 1.20% with denosumab, with the change rate of denosumab significantly increasing over that of bisphosphonates. The change rate in femoral BMD was 2.69 ± 1.16% with bisphosphonates and 2.95 ± 1.26% with denosumab, with no significant difference between the two groups. The rate of decrease in tartrate-resistant acid phosphatase isoform 5b was significantly higher in the denosumab group. The change rate in TBS at 24 months of treatment was 0.53 ± 1.26% in the bisphosphonates group and 1.08 ± 1.33% in the denosumab group, with no significant difference between the two groups. After 24 months, TBS remained stable.

Conclusion: Both bisphosphonates and denosumab may increase BMD, improve bone metabolism, and inhibit bone quality loss in patients with AIBL.

Abstract Image

查看原文本刊更多论文

双膦酸盐和地诺单抗治疗对日本乳腺癌 AIBL 患者 TBS 的影响

简介：双膦酸盐和地诺单抗可增加骨矿密度（BMD），用于治疗芳香化酶抑制剂相关骨质流失（AIBL）患者的骨质疏松症。本研究旨在直接比较双膦酸盐与地诺单抗在治疗AIBL患者中的作用，并确定地诺单抗对骨小梁评分（TBS）的影响：对接受骨质疏松症治疗的 39 例 AIBL 患者（双膦酸盐组 21 例，地诺单抗组 18 例）的腰椎和股骨 BMD、腰椎骨质量（通过 TBS 评估）和血液骨代谢标记物的变化进行回顾性评估。统计评估采用 Mann-Whitney 检验和 Wilcoxon 检验：治疗 24 个月后，双膦酸盐的腰椎 BMD 变化率为 5.82 ± 1.10%，地诺单抗的腰椎 BMD 变化率为 10.49 ± 1.20%，地诺单抗的变化率明显高于双膦酸盐。使用双膦酸盐的股骨 BMD 变化率为 2.69 ± 1.16%，使用地诺单抗的股骨 BMD 变化率为 2.95 ± 1.26%，两组之间无明显差异。抗酒石酸磷酸酶同工酶 5b 的下降率在地诺单抗组明显更高。治疗 24 个月时，双膦酸盐组 TBS 的变化率为 0.53 ± 1.26%，而地诺单抗组为 1.08 ± 1.33%，两组间无明显差异。24个月后，TBS保持稳定：结论：双膦酸盐和地诺单抗均可增加 AIBL 患者的 BMD，改善骨代谢，抑制骨质流失。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Bone and Mineral Metabolism 医学-内分泌学与代谢

CiteScore

6.30

自引率

3.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Bone and Mineral Metabolism (JBMM) provides an international forum for researchers and clinicians to present and discuss topics relevant to bone, teeth, and mineral metabolism, as well as joint and musculoskeletal disorders. The journal welcomes the submission of manuscripts from any country. Membership in the society is not a prerequisite for submission. Acceptance is based on the originality, significance, and validity of the material presented. The journal is aimed at researchers and clinicians dedicated to improvements in research, development, and patient-care in the fields of bone and mineral metabolism.